Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Shihui Lai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-3806-6442; OpenAlex author ID A5071981545. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2022: 4 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-025-08135-5↗
  2. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05715-1↗
  3. Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Co-author DOI 10.1038/s41419-023-05939-1↗
  4. The m6A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathw… Co-author DOI 10.1186/s12943-022-01647-0↗
  5. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway. Co-author DOI 10.1186/s13062-022-00347-5↗
  6. N6-methyladenosine-mediated CELF2 regulates CD44 alternative splicing affecting tumorigenesis via ERAD pathway in pancreatic cancer. Co-author DOI 10.1186/s13578-022-00844-0↗
  7. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by competitively sponging miR-139-5p and activating the W… Co-author DOI 10.21203/rs.3.rs-1242747/v1↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangeng Weng · 6 shared papers, 2022–2026 · strength 1.21
  2. Chengjie Lin · 5 shared papers, 2022–2026 · strength 1.03
  3. Xiang Zhang · 5 shared papers, 2022–2023 · strength 0.89
  4. Yan Wang · 5 shared papers, 2022–2023 · strength 0.86
  5. Zhenyun Guo · 3 shared papers, 2023–2026 · strength 0.70
  6. Liang Wang · 3 shared papers, 2022 · strength 0.51
  7. Yue Huang · 2 shared papers, 2023 · strength 0.39
  8. Chengjie Lin · 1 shared paper, 2022 · strength 0.17
  9. Yi Zhang · 1 shared paper, 2022 · strength 0.16
  10. Xiaomeng Liu · 1 shared paper, 2022 · strength 0.16
  11. Hongquan Wang · 1 shared paper, 2022 · strength 0.16
  12. Bo Tang · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.